Cardiovascular safety of growth hormone treatment in Noonan syndrome: real-world evidence.

Alicia RomanoJuan Pablo Pablo KaskiJovanna DahlgrenNicky KelepourisAlberto PietropoliTilman R RohrerMichel Polak

Published in: Endocrine connections (2022)

GH treatment had a favourable safety profile in patients with NS, including those with cardiovascular comorbidities. Prospective studies are warranted to systematically assess the safety of GH treatment in patients with NS and cardiovascular disease.

Keyphrases

cardiovascular disease
growth hormone
metabolic syndrome
case report
smoking cessation
cardiovascular risk factors